Should the customer need more than a di minimis amount of support they can choose to enter in to a separate contract for additional training.
On February 25, 2014 the shareholders approved an additional 1,000,000 shares increasing the total number of shares that may be granted under the Option Plan to 2,000,000.
Significant judgment is employed in determining the appropriateness of these assumptions as of the acquisition date and for each subsequent period.
Most of our contracts are of a duration of one year or less, few, if any of the longer-term contracts have commissions associated with them.
On June 1, 2017, the Company acquired DILIsym Services, Inc.
On May 15, 2014, we entered into a termination and nonassertion agreement with TSRL, Inc., pursuant to which the parties agreed to terminate an exclusive software licensing agreement entered into between the parties in 1997.
The accompanying notes are an integral part of these financial statements.
Four customers accounted for 13%, 9%, 7%, and 6% (a dealer account in Japan representing various customers) of net sales during the three months ended November 30, 2018.
Significant accounting policies for us include revenue recognition, accounting for capitalized computer software development costs, valuation of stock options, and accounting for income taxes.
Our Buffalo subsidiary leases approximately 12,623 square feet of space in Buffalo, New York.Many of these presentations are from industry and FDA scientists; some are from our staff.
We believe our investment to participate in this initiative enabled us to benefit from, and to contribute to, advancing the prediction of human oral bioavailability from preclinical data, and ensured that we are well-known to member pharmaceutical companies and regulatory agencies.
GastroPlus mechanistically simulates the absorption, pharmacokinetics, pharmacodynamics, and drug-drug interactions of compounds administered to humans and animals and is currently the most widely used commercial software of its type by pharmaceutical companies, the U.S. Food and Drug Administration (FDA), the U.S. National Institutes of Health (NIH), and other government agencies in the U.S. and other countries.
As chemists attempt to modify structures to improve one property, they often cause others to become unacceptable.
Thus, we compete not only with other software suppliers and scientific consulting service providers, but also with the in-house development and scientific consulting teams at some of the larger pharmaceutical companies.
This grant award, for $250,000 per year for up to two years, will focus on the incorporation of drug product quality attributes into dermal physiologically-based pharmacokinetic (PBPK) models developed for dermatological topical dosage forms and transdermal delivery systems.
Total research and development cost increased $168,000 in 1QFY19 compared to 1QFY18.
Researchers can also click on an icon to generate the likely metabolites of a molecule and then predict all of the properties of those metabolites from ADMET Predictor, including each of their ADMET Risk scores.